Ovarian Cancer Biology and Immunotherapy

REFERENCES

• Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62(1):10–29.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA A Cancer J Clin 2010;60(5):277–300.
   PubMed Web of Science ®Google Scholar
• Heintz AP, Odicino F, Maisonneuve P, Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet 2006;95(Suppl 1):S161–S192.
   PubMed Web of Science ®Google Scholar
• Saad AF, Hu W, Sood AK. Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer 2010;1(6):277–290.
   Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003;348(3):203–213.
   PubMed Web of Science ®Google Scholar
• Cannon MJ, Goyne H, Stone PJ, Chiriva-Internati M. Dendritic cell vaccination against ovarian cancer–tipping the Treg/TH17 balance to therapeutic advantage? Expert Opin Biol Ther 2011;11(4):441–445.
   PubMed Web of Science ®Google Scholar
• Weiss NS, Homonchuk T, Young JL, Jr. Incidence of the histologic types of ovarian cancer: the U.S. Third National Cancer Survey, 1969–1971. Gynecol Oncol 1977;5(2):161–167.
   Google Scholar
• Nicosia SV. The aging ovary. Med Clin North Am 1987;71(1):1–9.
   Google Scholar
• Salazar H, Godwin AK, Daly MB, Microscopic benign and invasive malignant neoplasms and a cancer-prone phenotype in prophylactic oophorectomies. J Natl Cancer Inst 1996;88(24):1810–1820.
   Google Scholar
• Fathalla MF. Incessant ovulation–a factor in ovarian neoplasia? Lancet 1971;2(7716):163.
   PubMed Web of Science ®Google Scholar
• Fredrickson TN. Ovarian tumors of the hen. Environ Health Perspect 1987;73:35–51.
   PubMed Web of Science ®Google Scholar
• Schildkraut JM, Schwingl PJ, Bastos E, Epithelial ovarian cancer risk among women with polycystic ovary syndrome. Obstet Gynecol 1996;88(4 Pt 1):554–559.
   Google Scholar
• Risch HA. Hormonal etiology of epithelial ovarian cancer, with a hypothesis concerning the role of androgens and progesterone. J Natl Cancer Inst 1998;90(23):1774–1786.
   PubMedGoogle Scholar
• Ness RB, Cottreau C. Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 1999;91(17):1459–1467.
   PubMed Web of Science ®Google Scholar
• Altinoz MA, Korkmaz R. NF-kappaB, macrophage migration inhibitory factor and cyclooxygenase-inhibitions as likely mechanisms behind the acetaminophen- and NSAID-prevention of the ovarian cancer. Neoplasma 2004;51(4):239–247.
   PubMed Web of Science ®Google Scholar
• Beral V, Bull D, Green J, Reeves G. Ovarian cancer and hormone replacement therapy in the Million Women Study. Lancet 2007;369(9574):1703–1710.
   PubMed Web of Science ®Google Scholar
• Syed V, Ulinski G, Mok SC, Expression of gonadotropin receptor and growth responses to key reproductive hormones in normal and malignant human ovarian surface epithelial cells. Cancer Res 2001;61(18):6768–6776.
   Google Scholar
• Hanna L, Adams M. Prevention of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2006;20(2):339–362.
   Google Scholar
• Gadducci A, Gargini A, Palla E, Polycystic ovary syndrome and gynecological cancers: is there a link? Gynecol Endocrinol 2005;20(4):200–208.
   PubMed Web of Science ®Google Scholar
• Rosenberg L, Zhang Y, Coogan PF, A case-control study of oral contraceptive use and incident breast cancer. Am J Epidemiol 2009;169(4):473–479.
   Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012;12(4):252–264.
   PubMed Web of Science ®Google Scholar
• Ben-Hur H, Gurevich P, Huszar M, Apoptosis and apoptosis-related proteins (Fas, Fas ligand, Blc-2, p53) in lymphoid elements of human ovarian tumors. Eur J Gynaecol Oncol 2000;21(1): 53–57.
   Google Scholar
• Paul P, Rouas-Freiss N, Khalil-Daher I, HLA-G expression in melanoma: a way for tumor cells to escape from immunosurveillance. Proc Natl Acad Sci U S A 1998;95(8):4510–4515.
   PubMed Web of Science ®Google Scholar
• Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392(6673): 245–252.
   PubMed Web of Science ®Google Scholar
• Arpinati M, Chirumbolo G, Urbini B, Role of plasmacytoid dendritic cells in immunity and tolerance after allogeneic hematopoietic stem cell transplantation. Transpl Immunol 2003;11(3–4):345–356.
   Google Scholar
• Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci 2010;1183:89–103.
   PubMed Web of Science ®Google Scholar
• Blasius A, Vermi W, Krug A, A cell-surface molecule selectively expressed on murine natural interferon-producing cells that blocks secretion of interferon-alpha. Blood 2004;103(11):4201–4206.
   PubMed Web of Science ®Google Scholar
• Blasius AL, Cella M, Maldonado J, Siglec-H is an IPC-specific receptor that modulates type I IFN secretion through DAP12. Blood 2006;107(6):2474–2476.
   PubMed Web of Science ®Google Scholar
• Yoneyama H, Matsuno K, Zhang Y, Evidence for recruitment of plasmacytoid dendritic cell precursors to inflamed lymph nodes through high endothelial venules. Int Immunol 2004;16(7):915–928.
   Google Scholar
• Zabel BA, Silverio AM, Butcher EC. Chemokine-like receptor 1 expression and chemerin-directed chemotaxis distinguish plasmacytoid from myeloid dendritic cells in human blood. J Immunol 2005;174(1):244–251.
   PubMed Web of Science ®Google Scholar
• Vanbervliet B, Bendriss-Vermare N, Massacrier C, The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. J Exp Med 2003;198(5):823–830.
   PubMed Web of Science ®Google Scholar
• Siegal FP, Kadowaki N, Shodell M, The nature of the principal type 1 interferon-producing cells in human blood. Science 1999;284(5421):1835–1837.
   PubMed Web of Science ®Google Scholar
• Ito T, Yang M, Wang YH, Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J Exp Med 2007;204(1):105–115.
   PubMed Web of Science ®Google Scholar
• Ito T, Hanabuchi S, Wang YH, Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008;28(6):870–880.
   PubMed Web of Science ®Google Scholar
• Conrad C, Gilliet M. Plasmacytoid dendritic cells and regulatory T cells in the tumor microenvironment: A dangerous liaison. Oncoimmunology 2013;2(5):e23887.
   PubMed Web of Science ®Google Scholar
• Goubier A, Dubois B, Gheit H, Plasmacytoid dendritic cells mediate oral tolerance. Immunity 2008;29(3):464–475.
   PubMed Web of Science ®Google Scholar
• Smit JJ, Rudd BD, Lukacs NW. Plasmacytoid dendritic cells inhibit pulmonary immunopathology and promote clearance of respiratory syncytial virus. J Exp Med 2006;203(5):1153–1159.
   Google Scholar
• Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol 2010;117(2):366–372.
   PubMed Web of Science ®Google Scholar
• Sharma MD, Baban B, Chandler P, Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007;117(9):2570–2582.
   PubMed Web of Science ®Google Scholar
• Curotto de Lafaille MA, Lafaille JJ. Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 2009;30(5):626–635.
   PubMed Web of Science ®Google Scholar
• Groux H, O'Garra A, Bigler M, A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997;389(6652):737–742.
   PubMed Web of Science ®Google Scholar
• Jonuleit H, Schmitt E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003;171(12):6323–6327.
   PubMed Web of Science ®Google Scholar
• Ramos RN, de Moraes CJ, Zelante B, Barbuto JA. What are the molecules involved in regulatory T-cells induction by dendritic cells in cancer? Clin Dev Immunol 2013;2013:806025.
   Google Scholar
• Sato E, Olson SH, Ahn J, Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005;102(51):18538–18543.
   PubMed Web of Science ®Google Scholar
• Curiel TJ, Coukos G, Zou L, Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med. 2004;10(9):942–949.
   PubMed Web of Science ®Google Scholar
• Kryczek I, Wei S, Zhu G, Relationship between B7-H4, regulatory T cells, and patient outcome in human ovarian carcinoma. Cancer Res 2007;67(18):8900–8905.
   PubMed Web of Science ®Google Scholar
• Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299(5609):1057–1061.
   PubMed Web of Science ®Google Scholar
• Zou W, Machelon V, Coulomb-L'Hermin A, Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat Med 2001;7(12):1339–1346.
   PubMed Web of Science ®Google Scholar
• Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995;1(1):27–31.
   PubMed Web of Science ®Google Scholar
• Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3(2):65–71.
   PubMedGoogle Scholar
• Frumovitz M, Sood AK. Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol 2007;104(3):768–778.
   Google Scholar
• Lokshin AE, Winans M, Landsittel D, Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer. Gynecol Oncol 2006;102(2):244–251.
   PubMed Web of Science ®Google Scholar
• Davidson B, Goldberg I, Reich R, AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients. Gynecol Oncol 2003;90(2):248–257.
   PubMed Web of Science ®Google Scholar
• Thaker PH, Deavers M, Celestino J, EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res 2004;10(15):5145–5150.
   PubMed Web of Science ®Google Scholar
• Gavalas NG, Liontos M, Trachana SP, Angiogenesis-related pathways in the pathogenesis of ovarian cancer. Int J Mol Sci 2013;14(8):15885–15909.
   PubMed Web of Science ®Google Scholar
• Li B, Lalani AS, Harding TC, Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy. Clin Cancer Res 2006;12(22):6808–6816.
   PubMed Web of Science ®Google Scholar
• Lawicki S, Bedkowska GE, Gacuta-Szumarska E, Szmitkowski M. The plasma concentration of VEGF, HE4 and CA125 as a new biomarkers panel in different stages and sub-types of epithelial ovarian tumors. J Ovarian Res 2013;6(1):45.
   PubMedGoogle Scholar
• Auersperg N, Ota T, Mitchell GW. Early events in ovarian epithelial carcinogenesis: progress and problems in experimental approaches. Int J Gynecol Cancer 2002;12(6):691–703.
   Google Scholar
• Daniel FB, Joyce NJ. 7,12-Dimethylbenz[a]anthracene–DNA adducts in Sprague-Dawley and Long-Evans female rats: the relationship of DNA adducts to mammary cancer. Carcinogenesis 1984;5(8):1021–1026.
   Google Scholar
• Nishida T, Sugiyama T, Kataoka A, Histologic characterization of rat ovarian carcinoma induced by intraovarian insertion of a 7,12-dimethylbenz[a]anthracene-coated suture: common epithelial tumors of the ovary in rats? Cancer 1998;83(5):965–970.
   Google Scholar
• Buters JT, Mahadevan B, Quintanilla-Martinez L, Cytochrome P450 1B1 determines susceptibility to dibenzo[a,l]pyrene-induced tumor formation. Chem Res Toxicol 2002;15(9):1127–1135.
   Google Scholar
• Lohff JC, Christian PJ, Marion SL, Hoyer PB. Effect of duration of dosing on onset of ovarian failure in a chemical-induced mouse model of perimenopause. Menopause 2006;13(3):482–488.
   Google Scholar
• Hoyer PB, Davis JR, Bedrnicek JB, Ovarian neoplasm development by 7,12-dimethylbenz[a]anthracene (DMBA) in a chemically-induced rat model of ovarian failure. Gynecol Oncol 2009;112(3):610–615.
   Google Scholar
• Craig ZR, Davis JR, Marion SL, 7,12-dimethylbenz[a]anthracene induces sertoli-leydig-cell tumors in the follicle-depleted ovaries of mice treated with 4-vinylcyclohexene diepoxide. Comp Med 2010;60(1):10–17.
   Google Scholar
• Orsulic S, Li Y, Soslow RA, Induction of ovarian cancer by defined multiple genetic changes in a mouse model system. Cancer Cell 2002;1(1):53–62.
   Google Scholar
• Connolly DC, Bao R, Nikitin AY, Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res 2003;63(6):1389–1397.
   Google Scholar
• Dinulescu DM, Ince TA, Quade BJ, Role of K-ras and Pten in the development of mouse models of endometriosis and endometrioid ovarian cancer. Nat Med 2005;11(1):63–70.
   PubMed Web of Science ®Google Scholar
• Wu R, Hendrix-Lucas N, Kuick R, Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell 2007;11(4):321–333.
   PubMed Web of Science ®Google Scholar
• Quinn BA, Brake T, Hua X, Induction of ovarian leiomyosarcomas in mice by conditional inactivation of Brca1 and p53. PloS One 2009;4(12):e8404.
   Google Scholar
• Hunn J, Rodriguez GC. Ovarian cancer: etiology, risk factors, and epidemiology. Clin Obstet Gynecol 2012;55(1):3–23.
   PubMed Web of Science ®Google Scholar
• Kinross KM, Montgomery KG, Kleinschmidt M, An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J Clin Invest 2012;122(2):553–557.
   PubMed Web of Science ®Google Scholar
• Roby KF, Taylor CC, Sweetwood JP, Development of a syngeneic mouse model for events related to ovarian cancer. Carcinogenesis 2000;21(4):585–591.
   PubMed Web of Science ®Google Scholar
• Zhang L, Yang N, Garcia JR, Generation of a syngeneic mouse model to study the effects of vascular endothelial growth factor in ovarian carcinoma. Am J Pathol 2002;161(6):2295–2309.
   Google Scholar
• Janat-Amsbury MM, Yockman JW, Anderson ML, Comparison of ID8 MOSE and VEGF-modified ID8 cell lines in an immunocompetent animal model for human ovarian cancer. Anticancer Res 2006;26(4B):2785–2789.
   Google Scholar
• Cho S, Sun Y, Soisson AP, Characterization and evaluation of pre-clinical suitability of a syngeneic orthotopic mouse ovarian cancer model. Anticancer Res 2013;33(4):1317–1324.
   Google Scholar
• Bellati F, Napoletano C, Ruscito I, Past, present and future strategies of immunotherapy in gynecological malignancies. Curr Mol Med 2013;13(4):648–669.
   Google Scholar
• Morse MA, Deng Y, Coleman D, A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. Clin Cancer Res 1999;5(6):1331–1338.
   PubMed Web of Science ®Google Scholar
• Stiff PJ, Czerlanis C, Drakes ML. Dendritic cell immunotherapy in ovarian cancer. Expert Rev Anticancer Ther 2013;13(1):43–53.
   Web of Science ®Google Scholar
• Santin AD, Bellone S, Underwood LJ, Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer. Minerva Ginecol 2002;54(2):133–144.
   PubMedGoogle Scholar
• Brossart P, Wirths S, Stuhler G, Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 2000;96(9):3102–3108.
   PubMed Web of Science ®Google Scholar
• Hernando JJ, Park TW, Kubler K, Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial. Cancer Immunol Immunother 2002;51(1):45–52.
   PubMed Web of Science ®Google Scholar
• Loveland BE, Zhao A, White S, Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma. Clin Cancer Res 2006;12(3 Pt 1):869–877.
   PubMed Web of Science ®Google Scholar
• Hernando JJ, Park TW, Fischer HP, Vaccination with dendritic cells transfected with mRNA-encoded folate-receptor-alpha for relapsed metastatic ovarian cancer. Lancet Oncol 2007;8(5):451–454.
   PubMed Web of Science ®Google Scholar
• Peethambaram PP, Melisko ME, Rinn KJ, A phase I trial of immunotherapy with lapuleucel-T (APC8024) in patients with refractory metastatic tumors that express HER-2/neu. Clin Cancer Res 2009;15(18):5937–5944.
   PubMed Web of Science ®Google Scholar
• Chiang CL, Kandalaft LE, Tanyi J, A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside. Clin Cancer Res 2013;19(17):4801–4815.
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Powell DJ, Jr., Chiang CL, Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013;2(1):e22664.
   PubMed Web of Science ®Google Scholar
• Defining the Role of CD4+CD25+ Immunoregulatory T-cells in the Treatment of Patients with Advanced Ovarian Cancer Who Receive Dendritic Cell Based Vaccine Therapies. Available at: http://clinicaltrails.gov/ct2/show/ NCT00703105 [accessed October 2012].
   Google Scholar
• Vaccination of Patients with Ovarian Cancer with Dendritic Cell/Tumor Fusions with GM-CSF and Imiquimod. Available at: http://clinicaltrails.gov/ct2/show/ NCT00799110 [accessed August 2013].
   Google Scholar
• Longuespee R, Boyon C, Desmons A, Ovarian cancer molecular pathology. Cancer Metastasis Rev 2012;31(3–4):713–732.
   Google Scholar
• Chereau E, Lambaudie E, Houvenaeghel G. Morbidity of surgery after neoadjuvant chemotherapy including bevacizumab for advanced ovarian cancer. Int J Gynecol Cancer 2013;23(7):1326–1330.
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Chen XH, Chang XH, Human embryonic stem cells–a potential vaccine for ovarian cancer. Asian Pacific journal of cancer prevention. Asian Pac J Cancer Prev 2012;13(9):4295–4300.
   Google Scholar
• Kandalaft LE, Powell DJ, Jr., Singh N, Coukos G. Immunotherapy for ovarian cancer: what's next? Journal of clinical oncology. J Clin Oncol 2011;29(7):925–933.
   PubMed Web of Science ®Google Scholar
• Kandalaft LE, Powell DJ, Jr., Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer. Oncoimmunology 2013;2(1):e22664.
   PubMed Web of Science ®Google Scholar